R&D Life Sciences Industry Report - Biologics and Generics The importance of biosimilars only continues to grow, driven by the potential savings they are able to deliver to healthcare systems.
News Medicare price negotiations 'will continue under Trump' President Trump will continue Medicare drug pricing negotiation but intends to look for improvements to the scheme according to CMS.
News Vaccines dominate questioning at RFK Jr's first hearing Robert F Kennedy Jr's first confirmation hearing was a fractious affair, marked by tough questions about his prior anti-vaccine stance.
News Lyfegen partners EVERSANA on pricing, access resource Lyfegen and EVERSANA have joined forces to help pharma companies navigate an increasingly complex global drug pricing and access environment.
News Trump pulls Biden policies on health insurance, drug pricing President Trump has started dismantling health legislation introduced under the Biden administration on day one of his new term.
News FTC doubles down on PBM criticism in new report A new FTC report claims that pharmacy benefit managers generated $7.3bn by marking up specialty generics used to treat diseases like cancer and HIV.
Market Access The value of a partner, globally and locally A new podcast looks at recent trends related to drug approvals, as well as challenges and opportunities both small and large pharma companies face
